YONKERS, N.Y. (June 16, 2011) – Aureon Biosciences, Inc. strongly committed to NY BIOHUD VALLEY, the City of Yonkers and Westchester County, has expanded yet again in i.park Hudson, taking another 8,000 square feet of commercial space.
“Aureon Biosciences started here 10 years ago,” Corporate Compliance Officer Dr. Charles J. DiComo said. “We continue to grow and plan on staying. NY BIOHUD VALLEY is where we want to continue to cultivate our business.”
Aureon now occupies the entire fourth floor, or 28,000 square feet, of the six-story building. In 2002, Aureon began operations with just its corporate headquarters and clinical labs occupying 14,000 square feet.
“Westchester County is very pleased to see the biotech sector taking off,” Westchester County Executive Robert P. Astorino said. “Aureon is a shining example of what NY BIOHUD VALLEY and the county are all about.”
The company has grown from 30 employees two years ago to more than 100 today and now has all company operations located in the office. Beyond the corporate headquarters and commercial clinical laboratories, Aureon now has customer service, sales and marketing, billing and reimbursement, research and development, and the financial team at the i.park facility.
“We’re so excited for Aureon Biosciences’ continuing growth and that the company will be a long-term member of NY BIOHUD VALLEY,” said Mike Oates, President and CEO of the Hudson Valley Economic Development Corporation. “The company is having enormous success by doing something incredible for patients in the field of cancer treatment. That success will attract even more life sciences companies to the region because they will see we have an intelligent, knowledgeable workforce.”
Aureon’s unique Systems Pathology platform is the foundation for Aureon’s personalized prognostic tools: Prostate Px+ and Post-Op Px. These tools combine cellular and molecular information to provide individualized, objective risk assessment for both newly diagnosed men with prostate cancer as well as men who have had surgery for the disease.
“Aureon Biosciences represents the true spirit of entrepreneurism, which is propelling Westchester County and the entire NY BIOHUD VALLEY region into a new era of economic growth,” stated Laurence Gottlieb, Director of Economic Development for Westchester County. “Being raised in Yonkers, I take great pride in seeing the city emerge as a major hub for biotech, as the life sciences become a critical component to building a brighter economic future for the region, with Aureon leading the way.”
About Aureon Biosciences: Aureon Biosciences mission is to enable personalized patient care through predictive pathology. Aureon has developed a high-throughput Systems Pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit www.aureon.com or call 1-888-SYS-PATH.
About Hudson Valley Economic Development Corporation (HVEDC): HVEDC represents seven counties in Hudson Valley. This public-private partnership markets the region as a prime business location to corporate executives, site selection consultants and real estate brokers. HVEDC also helped start the branding and promotional effort for NY BioHud Valley. For more information on Hudson Valley Economic Development Corporation or to review available business sites, visit www.hvedc.com or call CEO Mike Oates at 845-220-2244.
